News | November 14, 2022
Suven Life Sciences posts Q2FY23 consolidated loss at Rs. 23.18 Cr
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Subscribe To Our Newsletter & Stay Updated
